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GENERAL INTRODUCTION 
The antibiotic chlortetracycline (CTC) is administered frequently 
in veterinary medicine to treat infectious disease. Various 
investigators have found that divalent metal cations, present in animal 
feeds and drinking water, inhibit absorption. In addition, since CTC 
that enters the body is rapidly eliminated, achieving and maintaining 
therapeutic concentrations of drug in the blood/tissue can be difficult. 
The primary objective of this work was to study the pharmacokinetics 
of orally administering CTC alone and with citric acid (a metal chelator) 
in healthy and diseased turkeys. 
Explanation of Dissertation Format 
The work performed in this dissertation is presented in the form of 
two papers suitable for publication. The first paper, entitled "Oral 
Absorption of Chlortetracycline in Turkeys: Influence of Citric Acid 
and Pasteurella Multocida Infection", presents and discusses the 
experimental data collected. In the second paper, entitled "The 
Pharmacokinetics of Chlortetracycline Orally Administered to Turkeys: 
Influence of Citric Acid and Pasteurella Multocida Infection", a 
physiologically based pharmacokinetic model was used to study the 
absorption and elimination of CTC in the turkey. Reviews of general 
background information, of previous citric acid investigations and other 
pharmacokinetic studies with tetracyclines are found in this section and 
the introductions to the first and second papers, respectively. 
Following the papers, major conclusions are summarized and areas of 
future work are suggested. 
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Pharmacology 
The antibiotic CTC is widely used in disease treatment, food 
preservation, feed supplementation, and crop control because of its 
broad antibacterial spectrum and relative nontoxicity (1). 
Chemical properties 
The chemical properties of CTC effects the processes of absorption, 
distribution, and metabolism. The chemical structure of CTC is shown 
in the following diagram. It is an amphoteric, yellow, crystalline 
substance, and is usually supplied in the hydrochloride form to provide 
greater solubility. Due to the acidic pH of aqueous CTC solutions, 
painful parenteral injections are usually avoided (2). The most common 
route of administration is oral. 
Following oral administration of CTC, absorption of the antibiotic 
is highly dependent on the contents of the gastrointestinal tract. 
Albert and Rees (3) found that divalent and trivalent cations form 
CTC-metal complexes or chelates which have an inhibiting effect on 
absorption of CTC. Although the details are not discussed here, the 
chemical basis for the chelation of tetracyclines with divalent metal 
OH 0 OH O 
fONHz 
CI CHj OH NKHgig 
Chlortetracycline 
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ions are reviewed by Weinberg (4). 
In addition, findings indicate that tetracyclines not only bind to 
metals, but are strongly bound to proteins (5) . From 47-70% of the CTC 
in vivo is protein bound (6) . Readers interested in the mechanism of 
CTC-protein binding will find details in an article by Popov e£ (7). 
Since bound tetracyclines form larger molecules which are less mobile, 
the processes of absorption, distribution, and elimination (glomerular 
filtration) are affected. In addition, most authorities agree that the 
bound drug is biologically inactive. 
One of the primary routes of elimination of CTC is by chemical 
decomposition. Although the specific decomposition products depend 
largely on the pH of the solution, most degradation products of CTC have 
a low biological activity (0-43% of the original activity of CTC) (8) . 
Absorption 
Since CTC is usually administered orally, the resulting blood levels 
of antibiotic depend largely on the absorption processes. Although 
the absorption processes have not been extensively studied in the fowl, 
it is believed that the absorption rate is faster in birds than in most 
mammals due to the fowl's greater metabolic rate, higher body temperature, 
and shorter circulation time (9). 
In studies on dogs, tetracycline was found to be most rapidly 
absorbed from the duodenum and ileum (10) . Peak blood levels were 
reached within one-half hour after administration into the duodenum or 
ileum. Little absorption occurred in the colon. Consequently, a high 
rate of absorption would be expected a short time after drug enters the 
4 
fowl's small intestine. The rate of absorption would decrease as the 
drug enters the large intestine. 
According to the pH partition hypothesis, only the nonionized 
molecules are lipid-soluble and readily able to cross lipoidal membrane 
barriers. Although the tetracyclines are ionized throughout the 
physiological pH range, the highest level of zwitterion occurs at neutral 
pH values (11). The normal pH at various locations in the digestive 
tract of live chickens is shown in Table 1. By determining the 
Table 1. pH of the digestive tract of chickens (12) 
Location pH 
Mouth 6.75 
Proventriculus 3.17 
Gizzard 2.60 
Small intestine 6.67 
Large intestine 7.09 
octanol/buffer partition coefficients (Table 2), Colaizzi and Klink (11) 
found that the maximum lipid solubility of CTC is between 3.9 and 6.6. 
Due to their neutral pH values, rapid absorption might be expected in 
the mouth, esophagus, small intestine, and large intestine. However, 
since 50% of ingested feed is excreted within 4-5 hours after 
consumption (9), unless absorption of drug is very fast, a large amount 
of orally administered drug will be excreted. 
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Table 2. Partition coefficients (octanol/aqueous buffer) of 
tetracycline (TC) and CTC hydrochloride (11) 
pH 
Analog 3.0 3.9 5.6 6.6 7.5 8.5 
TC .007 .044 .056 .052 .036 .010 
CTC .180 .270 .410 .320 .130 .071 
Barber (13) indicates that the absorption of tetracyclines 
may be nonlinear. When increasing the oral dose of certain 
tetracyclines (oxytetracycline) in human subjects, the blood level 
obtained increases with the dose up to a dose of about 1.0 gram, but 
increasing the dose beyond this does not lead to significantly higher 
blood levels. Similarly, Mitscher (5), in reviewing the results of 
Finland and his colleagues, states that with repeated dosage, increasing 
the dose of tetracycline beyond .5 grams (administered every 6 hours) 
fails to give any higher blood levels. These results may be due to a 
saturation of the absorption route. 
Distribution and elimination 
Once in the blood stream, CTC enters the different tissues of the 
body at varying rates. Since a therapeutic level of drug is required 
at the site of infection, CTC must reach the infected tissue and/or 
fluids. When mice were given low dose intramuscular injections of CTC, 
the drug was found to concentrate primarily in the bone marrow, spleen, 
lymph nodes, liver, and kidney (6). At higher doses, CTC was found in 
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connective tissue, cartilage, and bone as well. Pleva and Schlee (14) 
studied residues of CTC in muscles and organs of chickens following the 
use of feed mixtures containing CTC. Although large CTC residues were 
found in the kidneys, a significantly lower concentration of CTC was 
found in the liver. Somewhat lower concentrations were found in the 
fowl's white and dark muscle. 
A substantial amount of evidence indicates that a large proportion 
of CTC is excreted in the feces regardless of the route of administration. 
Eisner and Wulf (15) recovered 41% of the intravenous dose of CTC in the 
animal's (rats, dogs) feces. In addition, investigators (6) have found 
that the concentration of CTC in the bile is 8 to 16 times that observed 
in the serum. An enterohepatic circuit has been postulated whereby CTC 
is excreted into the intestine via the bile and then reabsorbed and 
recirculated. The proportion of the drug not reabsorbed is excreted via 
the intestines. Lanman et a^ . (16) discuss specific mechanisms of 
reabsorption. The result of interest is that the reabsorption process 
could perform an important role in the elimination of CTC. 
The mechanism of excretion of tetracycline in the urine of 
chickens was studied by Pindell et al. (10). Using the circulation 
properties of the chicken (renal portal circulation), they concluded 
that tetracycline is passed into the urine by passive glomerular 
filtration. Large CTC complexes are not readily excreted into the 
urine. Thus, the rate of elimination by this route is dependent upon 
the amount of bound tetracycline. Considering these results, it was 
surprising to find that in uremic patients with renal failure the 
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half-life of microbiologically active CTC ~ 5.5 hrs) did not 
increase (17). Since fecal excretion of CTC is significant, there may 
have been an increased rate of biliary secretion. 
Anatomy and Physiology of the Fowl 
Although various experimental animals may be used in pharmacokinetic 
studies, turkeys were employed in this work because (1) absorption 
problems with CTC in fowl are reported, (2) many physiological processes 
in turkeys (e.g., enterohepatic circuit, glomerular filtration) resemble 
those in mammals, and (3) turkeys are inexpensive to purchase and 
maintain. Because the physiological processes largely effect absorption 
and disposition rates, the anatomy and physiology of the turkey is 
discussed. Most of this material was taken from avian physiology texts 
(18, 19). 
Gastrointestinal tract 
For materials poorly absorbed, the gastrointestinal flow rate 
largely effects the fraction absorbed. In fowl, the crop serves as a 
food reservoir or storage area. When the gizzard is empty, material 
bypasses the crop and enters the proventricuius directly. Material is 
rapidly transported from the crop, through the proventriculus, to the 
gizzard by peristaltic contractions (3-4 contractions/minute) 
originating up in the esophagus. Excitement retards crop contractions, 
while hunger stimulates contractions. 
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Ileum 
Jejunum 
Cranial 
oesophagus 
Crop 
Liver 
gall bladder Caecum 
Caudal 
oesophagus 
Cystic duct 
Bile duct 
Ileo-caec-colic 
junction 
Pancreatic ducts 
Colon 
Gizzard 
Cloaca 
Duodenum 
pancreas 
The general structure of the digestive tract of the fowl. 
As material enters the gizzard, it is mixed with 6-21 ml of gastric 
juice. Although the gizzard grinds coarse material, finely divided 
foods pass through the gizzard to the upper portion (duodenum) of the 
small intestine in minutes. Consequently, an aqueous solution 
(containing drug) is quickly transported to the small intestine (primary 
site of absorption). 
Materials pass through the intestines with peristalic and 
segmenting movements, thereby mixing the G.I. contents. In the turkey, 
3-4 duodenal peristalic contractions occur per minute, with each 
contraction lasting 4.6-9.4 seconds. Duodenal flows of 40-60 ml/hr 
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have been measured in cockerels fed a mash diet. As material passes 
down the small intestine, net fluid secretion occurs in the duodenum, 
while absorption occurs in the jejunum and ileum. Regurgitation of the 
duodenal contents into the gizzard and crop have been reported, 
suggesting reverse peristalsis. 
After material leaves the lower portion of the small intestine, it 
passes through the (relatively short) large intestine (where little 
absorption of CTC takes place), rectum, and cloaca. The urinary tract 
empties into the cloaca where urine is mixed with feces. 
Liver and bile 
The liver is bilobed with a hepatic duct leaving each lobe. The 
left duct leads directly to the duodenum, while the right duct has a 
branch going to the gall bladder for concentration and storage. 
Formation of bile by the liver is a continuous process and secretory 
rates of about 1 ml/kg/hr have been measured in fowl. The bile formation 
rate is important since CTC is concentrated in the liver and secreted 
in the bile. 
Renal function 
Although the fowl and mammalian kidneys differ anatomically, their 
basic function is similar. Renal elimination can occur by glomerular 
filtration and/or tubular secretion. Renal elimination of tetracycline 
in chickens occurs by glomerular filtration (10). Arterial blood is 
supplied to the glomeruli from the renal arteries and renal branches of 
the external iliac arteries. Reported glomerular clearance values 
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range from 1.5 to 3.0 ml/min kg. 
Circulation 
Drug is transported to the tissues through the circulatory system. 
The cardiac output in 14.5 kg male turkeys is 111 ml/min/kg with a 
heart rate of 149 beats/min. Blood flows to most of the organs or 
tissue regions are in parallel. An exception is the so-called "renal 
portal" system. The proventriculus, gizzard, and duodenum are drained 
by the gastroduodenal vein which empties into the hepatic portal vein 
(supplying the liver). The renal portal system collects blood from the 
hind part of the body (hind limbs, tail, hind gut) and delivers a 
portion of it to the kidney tubules. However, blood may be shunted 
from the kidney through the intestinal vessels to the liver or vice 
versa. Consequently, when a substance normally secreted by the tubules 
is injected into the leg vein, it is excreted first by tubules on the 
injected side before reaching the general circulation. This property is 
used to determine if a drug is excreted by tubular secretion. 
Pharmacokinetic Models 
Pharmacokinetic modeling may be defined as the mathematical 
description of the biochemical and physiological processes which 
determine tissue concentrations following drug therapy. The model can 
be used to provide mechanistic information, predict drug levels not 
experimentally determined (extrapolation), evaluate parameters difficult 
to measure (e.g., permeabilities), compare various drug formulations 
and preparations, schedule drug therapy (dosage size and frequency). 
11 
and/or define areas where existing experimental data are inadequate. 
Although a model describing physiological and biochemical events at 
the microscopic level seems natural, macroscopic descriptions can 
adequately describe tissue distributions and require considerably less 
information and detail. 
Physiological modeling 
In physiological modeling, the body is divided into subregions for 
which macroscopic mass balances are written. Each major subregion 
(compartment) contains tissues with similar pharmacological properties 
(e.g., rapidly equilibrated tissues) or defines an anatomical region 
(e.g., organ) of interest. The compartments are interconnected to best 
represent the natural physiology. Materials are carried into each 
compartment by blood flow, and distribution occurs between the 
intravascular, interstitial, and cellular space. 
Most drugs are readily transported across the capillaries into 
the interstitial fluid (20). In some cases, there is no significant 
delay in complete equilibrium between blood plasma and the extravascular 
region. The time required for such lipid soluble drugs to reach 
equilibrium may only be limited by plasma flow (flow limited). That 
is, the tissue permeability (k )^ is much larger than the regional 
perfusion rate (Q^ ). Consequently, plasma leaving the compartment is 
in equilibrium with the tissue and a thermodynamic distribution ratio 
exists (C , /C . = constant) (21). Flow limited compartments can 
plasma tissue 
be modeled as a single stirred tank. 
12 
However, in certain compartments transport limitations may exist 
across membrane (e.g., cellular) barriers (transport limited). In 
this case, the compartment must be subdivided (e.g., extracellular, 
intracellular). The intercompartmental flux can be defined by a 
saturable and/or passive process. As reliable transport parameters are 
difficult to obtain, flow limited conditions are too often assumed. 
Classical modeling 
The most commonly used pharmacokinetic model is the largely 
empirical "classical" model. Like the physiological model, this model 
assumes that various regions of the body can be represented by 
subregions or compartments. Within each compartment, property 
variations are ignored and perfect mixing is assumed. However, unlike 
the physiological model, the compartments are fewer and less well-defined. 
The number of compartments used in the classical model is determined 
by fitting (curve fitting) a sum of exponentials to the experimental 
data. The number of compartments is equal to the number of exponentials 
required to fit the concentration-time curve. Intercompartmental 
transfer is assumed to take place by a linear law and the unsteady-state 
dCi 
mass balances between compartments are of the form = E k^^C^. 
For constant k^ ,^ the solution is of the form 
B.t 
C. = Z A. .e 
1 1] 
Classical pharmacokinetic models are simple and useful when 
comparing different drug formulations or preparations. However, unlike 
the physiologically based models, the parameters in the classical model 
13 
do not usually correspond to actual anatomic and physiological parameters. 
Consequently, the empirical parameters can be difficult to interpret, 
provide little mechanistic information, and cannot be modified to 
describe altered physiological function. 
14 
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SECTION I: ORAL ABSORPTION OF CHLORTETRACYCLINE IN 
TURKEYS; INFLUENCE OF CITRIC ACID AND 
PASTEURELLA MULTOCIDA INFECTION 
17 
INTRODUCTION 
The antibiotic chlortetracycline (CTC) is frequently administered 
to turkeys and other fowl as a treatment for infectious diseases. There 
is, in general, a close correlation between the concentration of 
antibiotic in the animal's body fluids/tissues and the drug's clinical 
effectiveness. Since CTC is commonly administered in the bird's drinking 
water or feed, resulting blood levels of CTC are dependent upon the rates 
of absorption, distribution, metabolism, and excretion. Numerous authors 
report that divalent cations (e.g., calcium and magnesium) present in 
animal feeds and drinking water inhibit absorption (1-4). Consequently, 
there is considerable interest in developing methods to increase the 
amount of tetracyclines absorbed following oral administration. 
Eisner et (5) found that the oral administration of certain 
organic acids (including citric acid) enhanced the absorption of CTC 
from the gastrointestinal tract of rats, guinea pigs, and dogs. It was 
postulated that the mechanism of action for these organic acids was 
that of binding to metallic ions, thereby preventing their interference 
with absorption of the tetracycline (6). Clary £t al. (7), after 
having difficulty reaching therapeutic blood levels in turkeys, enhanced 
the absorption of CTC with citric acid by adding both in the drinking 
water. Similarly, Russell and Kruger (8) found that administering 
citric acid enhanced the absorption of oxytetracycline in chickens. 
In a recent study, our laboratory determined the serum 
concentrations in chickens following the oral administration of CTC 
alone and with citric acid (9). The addition of citric acid produced 
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significantly higher serum levels than when CTC was administered alone. 
The primary purposes of this study were to investigate the 
following in turkeys: 
1. The dose versus plasma level relationship when CTC is 
administered orally. 
2. The effect of citric acid on the absorption of CTC. 
3. Whether infection with multocida influences the 
absorption of CTC. 
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MATERIALS AND METHODS 
Animals 
The animals used were small Beltsville white turkeys initially 
eight weeks old and weighing an average of 1.8 kilograms. In most of 
the experiments, the error caused by weight differences among the birds 
was removed by "blocking out" weight (10). 
Drug Administration 
The CTC hydrochloride used was 97.1% pure. All drug solutions 
were prepared in distilled, deionized water and administered orally by 
gavage directly into the crop. Food was withdrawn from the birds 
17 hours prior to drug administration, but distilled, deionized water 
was supplied ^  lib. 
Sample Collection and Treatment of Samples 
Immediately before drug administration, a 3.0 ml blood sample was 
drawn from each bird's jugular vein. This sample served as an analytic 
base line. After each drug administration, 3.0 ml blood samples were 
collected from each bird at various times over the 24-hour period 
following administration. The samples were placed in tubes containing 
10.0 units of heparin (to prevent coagulation). However, during the 
first three weeks of the study, the birds were small; consequently, 
smaller 1.5 ml blood samples were collected and pooled from two birds 
of the same group and of similar weight. 
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The 3.0-ml blood samples were spun down in a clinical centrifuge 
at approximately 4000 rpm, and 1.5 ml of the resulting plasma was 
pipetted into a glass tube with a Teflon-lined cap. Tissue samples 
were washed of excess blood, placed in capped glass receptacles, and 
immediately put on ice. All biological samples were frozen at -15°C 
until the time of analysis to prevent CTC decomposition. Approximately 
10 minutes elapsed between the time the birds were killed and the time 
their tissue samples were placed in the freezer. The CTC in the plasma 
and tissue samples was determined fluorimetrically by means of a 
Turner Model III filter fluorometer (11). 
Treatment Descriptions 
It is desirable to administer CTC at a dose high enough to produce 
therapeutic concentrations without saturating the fowl's absorption 
process. Consequently, the proper dosage regimen was determined by 
orally administering various doses (10, 15, or 20 mg/kg) of CTC to the 
turkeys. 
Two weeks later, after allowing the birds to physically recover, 
the fowl were orally dosed with varying amounts of citric acid (0, 75, 
150, or 225 mg/kg) mixed with CTC (15 mg/kg). The drugs were dissolved 
in distilled, deionized water and the birds were allowed to drink only 
distilled, deionized water. As the birds were fasted 17 hours prior to 
drug administration, minerals in the gastrointestinal (GI) tract were 
minimized. 
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An experiment was conducted on 13-week-old birds to study the 
tissue distribution of CTC. The birds received an oral dosage of 
15 mg/kg CTC and were killed by decapitation at one of 3 different 
times (2.5, 8.0, and 24 hours) after administration. Prior to 
decapitation, blood samples were collected for plasma. Tissue samples 
were collected from the red muscle, white muscle, liver, kidney and 
brain; these samples were subsequently frozen. 
At 17 weeks of age, the birds were orally administered CTC 
(15 mg/kg) alone and mixed with citric acid (150 mg/kg). The drug (CTC) 
2+ 
was dissolved in water containing 0.3 g/1 Ca (as CaClg • 25^ 0) and 
2+ 2+ 2+ 0.1 g/1 Mg (as MgSO^ ). The same levels of Ca and Mg were placed 
2+ 2+ in the birds' drinking water. These concentrations of Ca and Mg 
are within the range of well water compositions reported in Iowa (12). 
A common use for CTC is the treatment of fowl cholera. We were 
interested in ascertaining whether turkeys infected with multocida 
and subsequently dosed with a CTC (15 mg/kg) + citric acid (150 mg/kg) 
mixture had blood levels of CTC which differed from the same birds when 
they were similarly treated but healthy. Plasma levels of CTC were 
determined initially in 12 healthy turkeys as indicated above. One week 
later these same birds were infected by intramuscular injection with 
2325 organisms of 2- multocida in the right breast. Eighteen hours 
after the birds were infected, they were orally dosed with the 
CTC-citric acid mixture as described previously. 
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RESULTS 
The plasma concentration curves representing turkeys orally dosed 
with 3 different amounts of CTC are presented in Figure 1. Plasma and 
tissue levels of CTC following the oral administration of 15 mg/kg CTC 
are presented in Table 1, 
The plasma levels resulting from the oral administration of varying 
amounts of citric acid combined with 15 mg/kg CTC are presented in 
Figure 2. Citric acid does not appear to enhance the uptake of CTC when 
minerals in the GI tract are minimized. Figure 3 displays the plasma 
concentrations of CTC following the concomitant oral administration of 
CTC and citric acid when the CTC was dissolved in water that contained 
Ca^ "*" (0.3 g/1) and (0.1 g/1). The same levels of Ca^  ^and 
were placed in the birds' drinking water. A statistical analysis (split 
plot (10)) indicates that, in the presence of minerals, the mean 
plasma level of the birds orally administered CTC + citric acid 
(C = 0.93) is significantly different (at the 5% level) than levels for 
the birds orally administered CTC alone (C = 0.35). 
The data resulting from the oral administration of CTC combined 
with citric acid to turkeys that were initially healthy and later 
infected with multocida are presented in Figure 4. A statistical 
analysis (split plot (10)) indicates that the differences in the shape 
of the two plasma concentration curves is not significant at the 5% 
level, but the mean plasma concentration was significantly (at 5% level) 
higher when the birds were infected (C = 1.5) than when they were 
healthy (C = 0.98). 
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Figure 1. Average plasma concentrations of CTC in turkeys 
(8 weeks old, 1.8 kg) following the oral 
administration of different doses (10, 15, and 
20 mg/kg) of CTC (n = 4 replications of each 
treatment) 
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Table 1. Concentration of CTC in tissue (yg/g) and plasma (yg/ml) 
samples following the oral administration of 15 mg/kg CTC to 
turkeys (n = 3). Results are expressed as the mean + 
standard deviation of the mean. Birds were 13 weeks old 
and weighed an average of 3.3 kilograms 
Time 
after _ 
adminis- egion 
tration White Red 
(hr) Plasma muscle muscle Liver Kidney Brain 
2.5 0.6 0.09 0.23 3.05 8.76 
(+0.44) (+0.06) (+0.16) (+2.01) (+7.24) 
8.0 0.44 0.15 0.28 2.32 10.84 0.05 
(+0.25) (+0.15) (+0.17) (+1.37) (+8.19) (+0.01) 
24.0 0.11 0.05 0.05 0.61 2.57 0.07 
(+0.05) (+0.02) (+0.04) (+0.44) (+0.35) (+0.05) 
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Figure 2. Average plasma concentrations of CTC in turkeys 
(10 weeks old, 2.3 kg) at various mean times 
following the oral administration of 15 mg/kg 
CTC combined with different amounts of citric 
acid (n = 4) 
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Figure 3. Average turkey (17 weeks old, 4.0 kg) plasma 
concentrations of CTC at various times following 
the oral administration of 15 mg/kg CTC alone (•) 
and with (o) 150 mg/kg citric acid. The CTC was 
dissolved in water containing calcium (0.3 
g/liter) and magnesium (0.1 g/liter). Results 
are expressed as mean + standard error of the 
mean (y + s/v'ïï), n = 12 
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Figure 4. Plasma concentrations in the turkey (22 weeks old, 
5.2 kg) following the oral administration of 
15 mg/kg CTC combined with 150 mg/kg citric acid 
when the birds (n = 12) were healthy (•) and 
later infected (o) with P. multocida. Results 
expressed as mean + standard deviation of the 
mean 
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DISCUSSION 
When the oral dosage of CTC was varied, the results suggested that 
in the dosage regimens studied, plasma levels are nearly linearly related 
to dose (see Figure 1). Because a dose of 15 mg/kg CTC produces a peak 
level of CTC high enough to combat most microorganisms, this was the dose 
employed throughout the study. 
It has been hypothesized that organic acids (such as citric acid) 
bind to divalent cations, thereby preventing their interference with the 
absorption of tetracyclines (6). This theory is supported by our data. 
When the amount of minerals present in the G1 tract was kept at a 
minimum, the addition of citric acid to the dosing solution had little 
2+ 2+ 
effect on the resulting CTC plasma levels. However, when Ca and Mg 
ions were present in the turkey's drinking water and in the CTC dosing 
solution, significantly higher drug levels were achieved with the 
addition of citric acid than when CTC was administered alone. 
These results may be compared with earlier work when CTC (25 mg/kg) 
was administered to chickens, both alone and in conjunction with citric 
acid (125 mg/kg) (9). Although the CTC was dissolved in distilled, 
deionized water, the chickens were allowed to drink tap water ^  lib. 
In this earlier study, significantly higher serum levels of CTC were 
achieved with the addition of citric acid. Apparently, the ions present 
in the tap water inhibited the absorption of CTC. 
The tissue levels resulting from the oral administration of 
15 mg/kg CTC (Table 1) provide valuable information regarding the 
distribution of CTC in the turkey. The low concentration of CTC in the 
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red and white muscle indicates that CTC does not readily enter muscle 
tissue. The high concentrations of CTC present in the kidney support 
earlier reports that the tetracyclines are secreted in the urine by 
glomerular filtration (13-16). The high levels of CTC present in the 
liver provide evidence that tetracyclines are concentrated in the liver 
and may be secreted in the bile (13, 14, 16). In addition, low levels 
of CTC in the brain are not surprising since most tetracyclines do not 
readily penetrate fatty tissue and the central nervous system (13). 
When 12 birds were infected with P^ . multocida and dosed with CTC 
combined with citric acid, the plasma levels were significantly higher 
than when these same birds were healthy (Figure 4). Because fowl 
cholera can alter the normal physiology of the GI tract and liver (17), 
higher than normal plasma levels in the infected fowl may result from an 
alteration of the processes (gut motility, pH, biliary secretion, etc.) 
which control the absorption and elimination of CTC. 
Of the twelve infected (2325 organisms/bird) birds orally dosed 
with CTC combined with citric acid, 5 birds died 3 days after 
administration of 2- multocida and 2 birds died 5 days after 
administration. Five of the birds were alive and healthy on the sixth 
day. However, all 10 control turkeys, infected with 2200 organisms of 
the same P. multocida culture, died within 2 days. Consequently, it 
appears that, as reported, CTC lowers the mortality from infection with 
P. multocida (17). 
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SECTION II: THE PHARMACOKINETICS OF CHLORTETRACYCLINE 
ORALLY ADMINISTERED TO TURKEYS: INFLUENCE 
OF CITRIC ACID AND PASTEURELLA MULTOCIDA 
INFECTION 
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INTRODUCTION 
Chlortetracycline (CTC) is a broad spectrum bacteriostatic 
antibiotic frequently used in veterinary medicine to combat microbial 
growth. Since CTC is poorly absorbed (inhibited by minerals in the 
gastrointestinal tract) and rapidly eliminated, therapeutic blood and 
tissue levels can be difficult to achieve and maintain. In this work, a 
physiologically based pharmacokinetic model was developed and used to 
study the effects of both citric acid and fowl cholera on the absorption 
and elimination of CTC in the turkey. 
The majority of previously reported pharmacokinetic studies involving 
tetracyclines have used the traditional two (1-5) or three (6) compartment 
models to describe serum or plasma profiles. In one earlier investigation 
in our laboratory, a two compartment model was used to describe the 
pharmacokinetics of orally administering CTC to chickens (7); the CTC 
was introduced both alone and with a metal chelator (citric acid). CTC 
increased the absorption rate; however, the hypothesized mechanism 
could not be verified with traditional modeling. 
An alternate type of pharmacokinetic model is a physiologically 
based model. Physiological models have been used to accurately describe 
concentration profiles of numerous substances in various species (8). 
Of these previous studies, the work of Olanoff and Anderson (9) is of 
particular interest because of its focus on tetracycline delivery (in 
the rat). However, because the fowl differs anatomically, when compared 
to other species, there remains a need to describe the pharmacokinetics 
of CTC in the turkey. 
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EXPERIMENTAL 
The purpose of the experimental work was to collect the data needed 
to 1) estimate pharmacokinetic model parameters in the healthy turkey, 
2) test and evaluate the pharmacokinetic model, 3) determine the 
mechanism by which citric acid enhances absorption of CTC in the 
presence of minerals, and 4) evaluate the pharmacokinetics in the 
diseased turkey. Because many of the experimental details are reported 
elsewhere (10), only highlights and previously unreported experiments 
are described. 
Animals 
The animals used in this study were small Beltsville white turkeys 
initially eight weeks old and weighing an average of 1.8 kilograms. 
Drug Administration 
All drug solutions were prepared in distilled, deionized water. 
Food was withdrawn from the birds 17 hours prior to drug administration, 
but distilled, deionized water was supplied ^  lib. CTC was orally 
dosed (by gavage) alone (15 mg CTC/kg) and in a mixture with citric 
acid (150 mg citrate/kg). CTC was given intravenously (IV) (1 mg CTC/kg) 
as a bolus injected into the right jugular vein. 
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Analytical Procedures 
Phenolsulfonphthaleln assay 
The fecal samples, containing phenolsulfonphthaleln, were mixed 
with distilled water (1:1) and centrifuged at 2500 rpm. Two milliliters 
of the supernatant were mixed with 2 ml of 1.0 N NaOH and the ODcco 
determined. 
Radiochemical assay 
Labeled polyethylene glycol - PEG, M.W. 4000) concentration in 
0.2 ml gut samples was determined by liquid scintillation counting. 
Quenching was corrected by employing external standards. 
CTC assay 
Concentrations of CTC in plasma and tissue were determined 
fluorometrically (11). 
Parameter Estimation 
The parameters employed in the pharmacokinetic model are displayed 
in Tables 1 and 2. 
Volume of gut lumen 
The volume (V^ )^ of the fowl's gastrointestinal lumen is highly 
dependent on the experimental conditions. The lumen volume was estimated 
with the following expression; 
I^L ~ 
(1) 
36 
Table 1. Compartmental parameters used in the pharmacokinetic model 
Parameter Estimate 
Bile to liver concentration ratio^ , 20 
"b c 
Renal clearance ' , 5.1 ml/min 
Unbound fraction of CTC in plasma, bile, liver, 0.59 
carcass 
Unbound fraction of CTC in intestinal lumen, F^  ^ 0.34-0.98 
Decomposition rate constant^ , 0.00015 1/min 
Biliary flow^ '®, Qg 0.05 ml/min 
Fecal flow^ , Qp 0.13 ml/min 
Intestinal permeability^ '®. Region 1, ^ 2 0.0047 ml/min 
Intestinal permeability^ '®. Region 2, ^13 0.0106 ml/min 
Intestinal permeability^ '®. Region 3, ^ 14 0.0059 ml/min 
Intestinal permeability^ '®. Region 4, kl5 0.0045 ml/min 
Carcass permeability^ , k^  5.5 ml/min 
Liver transport parameter^ , 4.7 ml/min 
V^alue estimated from Reference 12. 
V^alue scaled (13) to 3.3 kg turkey. 
G^lomerular filtration rate for fowl (14). 
"^ Calculated from decomposition data (15). 
R^eference 12. 
P^arameter providing best least squares fit to data. 
I^ntestinal permeabilities proportioned in accordance with 
Reference 16 (i.e. k^  ^= 0.44 k^  ^= 0.8 k^  ^= 1.04 k^ )^. 
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Table 2. Physiological volumes and plasma flows used in the model^  
Volume (Vi)^  Plasma flow^  
Region 
'S CO i o (Qi) ml/min 
Plasma 116 ml 320 
G.I. plasma 7.3 ml 36 
G.I. lumen 1 7 ml — 
G.I. lumen 2-4 15.7 ml 
Total lumen volume 54 ml 
Liver plasma 24 ml 61 
Liver tissue 22.8 g • —  
Carcass*^  (rapid equil.) 483 ml 259 
Carcass (slow equil.) 2358 g —  
Values are scaled (13) for a 3.3 kg turkey. 
P^lasma volumes were estimated from References 17 and 18. 
P^lasma flows were estimated from References 19-22. 
C^arcass volume corresponds to inulin space (23). 
\diere = initial dose of tracer (counts) and 
= volume averaged tracer concentration in the G.I. 
lumen (counts/ml). 
Since the thickness of the liquid layer on the inner surface of the gut 
was observed to be relatively constant throughout the gastrointestinal 
tract, a surface area (irr^ ) averaged concentration was used to estimate 
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The experimental procedure involved orally dosing 6 fasted (16 
hours) 3.8 kg turkeys with a predetermined amount of nonabsorbable (24) 
tracer (^ C^ - PEG). Each bird was killed one hour after drug 
administration and lumen samples were collected from the crop, duodenum, 
upper intestine, and lower intestine. The low concentrations of PEG 
found in the large intestine (Table 3) indicate that little tracer was 
lost in the feces. 
Table 3. Concentrations of PEG in the gastrointestinal lumen of a 
turkey one hour after 7.4 ml of - PEG (63550 counts/ml) 
were placed in the bird's crop 
Region Concentration 
(counts/0.2 ml) 
Crop 8145 
Duodenum 3317 
Upper small intestine 315 
Lower small intestine and colon 20 
Fecal flow rate 
Although the rate at which material passes through the gut can be 
highly irregular (dependent on the fowl's emotional state and gut 
contents (25)), an average flow rate (Qp) may be estimated by dividing 
the total volume of the gut lumen (V^^) by the mean transit time (T ) .  
The transit time was estimated by orally dosing the birds with 
phenolsulfonphthalein (1 mg/kg of 0.5 mg/ml phenolsulfonphthalein) and 
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measuring the concentration of dye in the feces as a function of time, 
Phenolsulfonphthalein was used because it is poorly absorbed (26) and 
easy to assay colorimetrically. The resulting fecal concentration 
versus time curve is shown in Figure 1. The calculated (27) transit 
time, t = (J^  tCpdt)/(J™ C^ dt), was 6.75 hours. 
Binding 
In the plasma, tetracyclines are reversibly bound to albumins, 
globulins, and lipoproteins (28). Reported values (29) of the fraction 
bound in plasma are from 47 to 70 percent; with the percent of bound 
tetracyclines found to be constant over a wide range of concentrations 
(.1 - 10 yg/ml) (30). 
With our assay procedure, most bound CTC is not recovered. When 
plasma samples were spiked with CTC, 41% was not recovered, and hence, 
this value represents a lower limit on the fraction bound. As information 
is not available on CTC binding in turkey tissues, this conservative 
estimate (0.41) was used for the fraction bound in all tissues. 
Because the carcass compartment consists of several tissue types, this 
estimate represents the mass average of strong (e.g., bone (31)) and 
weak binding tissues. 
CTC-Mineral-Citrate Binding 
The acid-base and metal binding expressions for CTC and citric 
acid are presented in Figure 2. The mass balances describing a mixture 
of CTC, metal cations, and citric acid are given in Equations (2-5). 
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Figure 1. Distribution of phenolsulfonphthalein in turkey 
feces following oral administration 
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pKa = 3.3 pKa = 7.44 pKa = 9.27 
, c , c" . c^-
+ H"^  + H"^  + H"*" 
pK = 3.8 
C + M CM (below pH = 9.3) 
pKa = 3.1 pKa = 4.8 pKa = 6.4 
A ' A" • A^ - • A^ -
+ H"*" + H"*" + H"^  
pKa = 3.2 
3_ +2 A + M MA. 
Figure 2. The ionization and chelation reactions reported in 
the literature. Ionization and stability constants 
are from References 32-35 (C = CTC; M = metal 
(Ca^  ^or Mg2+); A = citric acid) 
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CTC (C) Balance 
ICTC]j.^ q = [c"^ ] + [C] + [C"] + [CM^ ] (2) 
Metal (M) Balance 
+ [CM"^ ] + [MA~] (3) 
Citric Acid (A) Balance 
[A]^ q^ = [A] + [A'] + [A^ "] + [A^ ~] + [MA"] (4) 
Balance 
IH"^ ] = + [C] + 2[C~] + 2[CM+] + [A"] 
+ 2[A^ ~] + 3[A^ ~] + 3[MA"] (5) 
Assuming a constant pH, due to gastrointestinal buffering. 
Equations (2-5), combined with the appropriate ionization and stability 
expressions, leads to a relation describing the equilibrium 
concentrations of bound and free drug as a function of the initial 
concentrations of CTC, minerals, and citric acid. Solution of this 
relation gives Figure 3. For the experimental conditions, with and 
without citric acid, the free fractions of CTC are predicted to be 
0.98 and 0.34, respectively. 
Model Development 
The following assumptions, described in previous or subsequent 
sections, were made in formulating the pharmacokinetic model: 
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CITRATE OPTIMIZATION 
PH=6.67 
o 
o 
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RATIO OF CITRATE/CTC 
5.00 7.50 
Figure 3. Theoretical relationship between the unbound fraction 
of CTC and the citrate/CTC ratio; pH = 6.67, 
0.3 g/1 Ca2+, 0.1 g/1 Mg2+, and 7 g/1 CTC 
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1) Tissues with similar properties may be lumped together. 
2) Each lumped compartment may be represented by a well-mixed tank. 
3) Transport and elimination occurs by first-order kinetics. 
4) CTC readily crosses capillaries and equilibrates with 
easily diffusible interstitial fluids. 
5) Only the free component of drug crosses membrane barriers or 
decomposes. 
6) The free fraction of CTC in plasma/tissues remains constant. 
The turkey is represented by 4 compartments (plasma, liver, 
gastrointestinal, and carcass) (see Figure 4). Each region is 
characterized by an average concentration varying in time. The 
compartmental macroscopic mass balances, describing the change in CTC 
levels within each compartment, are given in the Appendix A. 
To determine if transport limitations exist, the liver and carcass 
compartments were each divided into rapidly (interstitial fluid and 
plasma) and slowly (intracellular) equilibrating fluid subregions. Mass 
transfer between carcass subregions was described as 
Net transfer = k^  ^ p^^ ci ~ ^ C2^ C2^  ~ ^  *^ 12 " 
Transfer of drug between the gastrointestinal lumen and plasma was 
described by a similar expression (see Appendix A). 
Uptake of drug by the liver was modeled as a nonsaturable first-
order process (K^ FpC^ )^. Because most materials are thought to enter 
the bile canaliculi after first entering the parenchymal cells (36, 37), 
transport into the bile was calculated as 
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Figure 4. Diagram of the physiologically based pharmacokinetic 
model of CTC absorption and disposition in the 
turkey. Solid lines indicate flows between regions 
and dashed lines indicate regions where 
intercompartmental transfer is concentration 
dependent. Chemical decomposition occurs in all 
compartments 
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Biliary transfer = • 
Elimination of CTC occurs by renal excretion, fecal excretion, and 
chemical decomposition. Chemical decomposition was described as a 
first-order rate process as observed in the dog (15). Since renal 
elimination of tetracycline in the fowl occurs by glomerular 
filtration (16), renal elimination was given by the glomerular 
clearance rate. For elimination via fecal flow, one must account for 
the mixing and dilution of the bolus dose as it moves down the 
gastrointestinal tract. 
Four tanks in series (Figure 4) were required to describe the exit 
age distribution (Figure 1) determined from nonabsorbable tracer 
studies. Tank 1 represents the volume (and concentration) of tracer 
administered to the birds at time = 0. Transport of drug occurs 
between each tank and the gastrointestinal plasma. Since the highest 
rate of absorption of tetracycline occurs in the upper portion of the 
small intestine (16), higher permeabilities were used in the first two 
tanks. 
An alternative model considered was a single tank with variable 
volume. As solute is transported throughout the gut, it distributes 
into a larger volume (V^ ^^ t)) with a larger surface area for 
absorption. Fecal elimination (Q^ ) does not begin until the drug 
reaches the end of the large intestine (at t = t^ ). As an approximation 
to the distribution process, ^ ^^ (t) and k^ (t) were described by linear 
functions. For t < t^ . 
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I^L (t/tE)(V(tg) - Vjj^ ) 
kj.(t) kj 
where V°^  = volume of dose. Finally, for t ^  t^ ; 
QpCt) = Qp 
kj(t) = k; 
Solution 
When the 'tanks-in-series' model is used to describe flow through 
the gut, the entire physiological model is described by a system of 
first-order differential equations of the form; 
C = AC = B 
where C' = vector of concentration derivatives, 
A = constant coefficient matrix, 
C = vector of compartmental concentrations, and 
B = vector of concentrations at time = 0. 
The analytical and numerical solutions, available elsewhere (38), were 
solved on a digital computer, employing various routines in the IMSL 
library (39). Permeabilities were estimated with an (IMSL) iterative 
least squares routine. 
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RESULTS AND DISCUSSION 
Oral Administration 
Figures 5a, 5b, and 5c display the fitted (tanks in series model) 
and observed concentration profiles following the oral dosage of 
15 mg/kg of CTC to healthy turkeys. The permeabilities used in the 
model were shown in Table 1. 
The low permeabilities relative to the regional perfusion rates 
(ki/Qi « 1) and existence of a nonlinear relationship between 
experimental tissue and plasma concentrations (Table 1 of Reference 10) 
suggest transport limitations from lumen to plasma and between certain 
tissues. Low permeabilities would be consistent with the observation 
that CTC occurs predominantly in an ionized (membrane insoluble) state 
(40, 41). 
Simulations which model the gut lumen as one variable volume 
stirred tank are shown in Figures 6a, 6b, and 6c. Permeability values 
(ml/min) for the gut, liver, and carcass are 0.034, 4.7, and 5.5, 
respectively. The fit is inferior to that of Figures 5a, 5b, and 5c, 
but could be improved were the higher permeability gut region 
incorporated. 
A simulated comparison of all routes of drug transport and 
elimination was made by integrating the appropriate transport term over 
time (Table 4). As the literature suggests (15), biliary secretion 
accounts for a significant portion of CTC elimination. Chemical 
decomposition accounts for less than 5% of elimination. However, the 
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Figure 5a. Concentration profiles of unbound CTC in the plasma 
following oral administration (15 mg/kg). 
Experimental and simulated (lumen modeled as tanks in 
series) concentrations at 24 hours are 0.10 and 0.08, 
respectively. Error bars represent the standard 
error of the mean (SEM) = 4 S^ /n " 0.16 
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Figure 5b. Concentration profiles of total CTC in the liver 
following oral administration (15 mg/kg). Experimental 
and simulated (lumen modeled as tanks in series) 
concentrations at 24 hours are 0.61 and 0.23, 
respectively. SEM = 0.82 
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Figure 5c. Concentration profiles of total CTC in the carcass 
tissue following oral administration (15 mg/kg). 
Estimated and simulated (lumen modeled as tanks in 
series) concentrations at 24 hours are 0.29 and 0.28, 
respectively. 
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Figure 6a. Concentration profiles of unbound CTC in the plasma 
following oral administration (15 mg/kg). 
Experimental and simulated (lumen modeled as variable 
volume) concentrations at 24 hours are 0.10 and 0.10, 
respectively. SEM =0.16 
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Figure 6b. Concentration profiles of total CTC in the liver 
following oral administration (15 mg/kg). Experimental 
and simulated (lumen modeled as variable volume) 
concentrations at 24 hours are 0.61 and 0.30, 
respectively. SEM =0.82 
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Figure 6c. Concentration profiles of total CTC in the carcass 
tissue following oral administration (15 mg/kg). 
Estimated and simulated (lumen modeled as variable 
volume) concentrations at 24 hours are 0.29 and 0.33, 
respectively 
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Table 4. Percent of CTC absorbed and eliminated in the presence of 
minerals (0.1 g/1 0.3 g/1 Ca^ "*"), as based on model 
calculations 
Percent of oral Percent of absorbed drug eliminated by: 
Treatment dose absorbed Reaction Renal Biliary 
CTC alone 6 4 50 46 
CTC + citric acid 16 4 49 47 
reactive rate constant used in the model describes the decomposition of 
CTC in dog urine; constants may differ in other tissues. 
Intravenous Administration 
Simulation of the IV data is displayed in Figure 7. The good 
agreement of the basic model with the first data point (t = 2 min) 
indicates that the model adequately describes the early, rapid 
distribution process. However, at later times, the experimental 
plasma data show a more rapid decline of drug than the model predicts. 
Although an alternate route of administration can provide a 
rigorous test for a model, it is not uncommon for the simulation to 
inadequately describe the data. Toutain and Raymaud (3) found that the 
elimination half-life (t, following the IV dosing of OTC to cattle 
was shorter than t^ ^^  ^for intramuscular (IM) administration. They 
hypothesized that only a small fraction of the IM dose is immediately 
available for transport, suggesting that a model with rapid and slow 
release compartments is required. 
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Figure 7. Experimental and simulated concentration profiles of 
unbound CTC in the plasma following intravenous 
administration (1 mg/kg) 
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Possible reasons this model does not adequately describe both 
the IV and oral data are the following: 
1) Rapid IV administration of high bolus doses may induce 
conditions (e.g., nonlinear binding) that invalidate 
certain model assumptions. 
2) A rapid distribution phase with strong binding may exist 
in regions (e.g., bone) not sampled. 
3) The gastrointestinal transport parameter may be higher 
when drug is transported from plasma to lumen than 
from lumen to plasma. 
Items 2 and 3 above were tested by adjusting parameters of the existing 
model. 
When a highly bound (F^  = .1) rapid distribution (k^  = 80 ml/min) 
phase is incorporated into the model, the result is as shown in 
Figures 7, 8a, and 8b. Although the intravenous plasma fit (Figure 7) is 
improved, the oral simulation (Figure 8a) peaks early with high levels 
at longer times. However, this model assumed linear, concentration 
dependent binding. If CTC located in the rapid distribution region 
was tightly bound, then the material would be released more slowly 
into the plasma. However, the predicted carcass concentrations 
(Figure 8b) with this hypothesis are unrealistically high. 
Although certain studies (42, 43) indicate that intestinal 
secretion may account for a significant portion of tetracycline 
elimination, other investigators (15) indicate that little CTC is 
transported from plasma to lumen. When the coefficients describing 
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Figure 8a. Concentration profiles of unbound CTC in the plasma 
following oral administration (15 mg/kg). Simulations 
use intravenous parameters 
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Figure 8b. Concentration profiles of total CTC in the carcass 
tissue following oral administration (15 mg/kg). 
Simulations use intravenous parameters 
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transport from plasma to lumen (i.e. K22_g(PL) = 20.0, 45.0, 25.0 and 
19.3, respectively) are assumed higher than from lumen to plasma 
(i.e. K22_gCLP) = 0.044, 0.099, 0.055 and 0.042, respectively), the IV 
fit is improved (Figure 7), but description of the oral data (Figures 8a 
and 8b) is inadequate. 
These simulations indicate that the present model is not capable of 
describing both oral and IV administration. Apparently, certain model 
assumptions (e.g., linear binding, well-mixed) become invalid with 
rapid IV administration. However, the model does provide a good 
description of the oral data. 
Effect of Citric Acid 
Figure 3, representing the unbound fraction of CTC (in the gut 
lumen) with increasing citric acid, indicates that a considerably 
higher unbound fraction of CTC is available with citric acid (F^  = 0.98) 
than without (F_ = 0.34). When these unbound fractions (F^ ) are 
X 1 
substituted into the model (without altering the other model parameters), 
the simulation (Figure 9) predicts the plasma profiles well. Thus, 
these simulations support our previous hypothesis that citric acid 
increases the rate of absorption by providing a larger fraction of 
unbound CTC for absorption. 
The addition of citric acid increased the fraction of drug 
absorbed from 6 to 16 percent (Table 4). Because disposition parameters 
were not altered when simulating the citrate data, these parameters do 
not appear to be significantly affected by citric acid. 
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Figure 9. Experimental and simulated concentration profiles of 
unbound CTC in the plasma following the oral 
administration of CTC alone (15 mg/kg) and with citric 
acid (150 mg/kg). SEM = 0.35 
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Effect of Fowl Cholera 
Pharmacokinetics frequently change in the diseased state due to 
alterations in plasma perfusion, hepatic function, drug binding, drug 
transport, and/or renal function (44). Consequently, the 
pharmacokinetics (of CTC) in infected (P. multocida) turkeys were 
compared with those in healthy birds. 
The birds used in the diseased study were older and larger than 
those used in the other studies; consequently, older control (healthy) 
birds were used. Following the oral administration of CTC, the plasma 
profiles in older (5.2 kg), healthy turkeys peaked earlier than those in 
younger (3.3 kg) birds. The investigation of this phenomenon with the 
pharmacokinetic model indicates that the original (simulation A, Table 5) 
gastrointestinal permeabilities appear to be modified, with the upper 
portion of the gut contributing more to absorption (simulation B, 
Table 5). The altered gut permeabilities appear to represent an age-
induced change in the physical characteristics of the gut (e.g., A pH, 
more surface area, etc.). 
When plasma profiles of CTC in diseased birds were compared to 
profiles in healthy birds, concentrations of CTC were consistently higher 
in the diseased birds (Figure 10). Although fowl cholera can produce a 
wide range of physiological changes (45), only those changes that could 
increase plasma levels were simulated (Table 5, Figure 10). When 
gastrointestinal permeabilities are increased (simulation C, Table 5), 
the early time data is described well; however, simulated concentrations 
are low at later times. On the other hand, lowering the hepatic 
Table 5. Model parameters in healthy and infected (JP. multocida) turkeys (see text for simulation 
descriptions) 
Simu- Age Condition Parameters (ml/min) 
la t ion (weeks) 1^2 1^3 kl4 1^5 k c Kl 
A 13 healthy 0.0047 0.0106 0.0059 0.0045 5.5 4.7 0.13 
B 22 healthy 0.0164 0.0080 0.0074 0.0057 9.5^  7.0* 0.20* 
C 22 diseased 0.0249 0.0121 0.0113 0.0087 9.5* 7.0* 0.20* 
D 22 diseased 0.0164 0.0080 0.0074 0.0057 9.5* 0.0 0.20* 
E 22 diseased 0.0200 0.0097 0.0090 0.0069 9.5* 1.7 0.20* 
P^arameters scaled (13) to describe 5.2 kg turkeys. 
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Figure 10. Experimental and simulated concentration profiles 
of unbound CTC in the plasma following the oral 
administration of CTC (15 mg/kg) + citric acid 
(150 mg/kg) to healthy and diseased turkeys. 
SEM = 0.29 
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clearance (simulation D, Table 5) produces low concentrations at early 
times, but higher concentrations at later times. When both the 
gastrointestinal permeabilities and hepatic clearance were optimized 
(simulation E, least squares best fit), the plasma data were adequately 
described. 
Because lesions of the liver are a clinical manifestation of fowl 
cholera, a decrease in hepatic clearance appears likely. A possible 
explanation for disease increasing gastrointestinal permeabilities is 
that the presence of pathogenic bacteria in the gastrointestinal tract 
may alter the pH of the lumen, thereby changing the fraction of 
unionized (absorbable) CTC. An alternate explanation is that certain 
chemicals (i.e. histamine, endotoxins), released by damaged tissues and 
bacteria, increase capillary permeabilities. If these substances also 
increased the permeabilities of surrounding, uninfected, tissues, then 
the overall gastrointestinal permeability could increase. 
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APPENDIX A: MODEL EQUATIONS 
Plasma: 
d C. 
P^ dt L^^ l C^^ Cl " ^ P^ P^^ C p^Vp^  S 
Gastrointestinal plasma, region 1: 
d 
Vji - QjCp + kj^ f^ iz^ iz ~ ^ P^ ii) + ^ 3 (^ 13^ 13 
+ ^ 14 ^ 1^4^ 14 ~ Fp^ ii) •*" 5^ (^ 15^ 15 " ^P^ Il^  
(Ql + Vj^ K^ Fp) Cji 
Gastrointestinal lumen, region 2; 
Vi2 âF" " ^12 (Fp^ il " ^12^ 12^  ~ •*" ^ I2Vl2^  ^ 12 
Gastrointestinal lumen, region 3: 
'l3 dt" ^  ^B®r''L2 '*' ^ 13 F^^ I2 
- «F + ^ I3Vl3> '=13 
Gastrointestinal lumen, region 4; 
1^4 ~dt " ^14 (^ P^ Il " ^14^ 14^  •*• " ^ "^ F 1^4^ 14^  ^ 14 
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Gastrointestinal lumen, region 5: 
1^5 dt" " ^15 " ^15^ 15^  I^sVlS^  *^ 15 
Liver plasma: 
\i ^  = "I'^ ii + «L - Qi) Cp - <VP + Si + \iW 'h.i 
Liver tissue: 
\2 ~dt~ ^ Vp^ Ll " \2VL2^  ^-LZ 
Carcass (rapidly equilibrating); 
^C1 dt" ^  ^C " ^Cl) (^ ca^ c^ cz ~ ^ P^Cl^  ~ ^ iVp C^I 
Carcass (slowly equilibrating); 
C^2 dt" ^  ^C (^ P^ ci - Fcz^ c^ cz) " ^CZVCZ^ CZ 
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APPENDIX B: NOMENCLATURE 
General 
2 A Surface area perpendicular to transport, cm 
Concentration ratio of bile to liver (Cg/C^ g) 
C Total tissue concentration, yg/ml or Ug/g 
d^  Density of carcass tissue, g/ml 
F Fraction of CTC unbound 
2 J Mass flux, yg/min cm 
k Permeability, ml/min 
K First order transport coefficient, ml/min 
Decomposition rate constant, 1/min 
M Mass of compartment, g 
Q Flow rate, ml/min 
Qg, Qj., Q^ , Qp Flow rates of plasma in carcass, intestine, liver, and 
plasma, respectively, ml/min 
Q Flow rate of bile, ml/min 
Qp Flow rate of feces, ml/min 
R^  Renal clearance rate, ml/min 
t Time, min 
V Volume of compartment, ml 
Subscripts 
C Carcass 
CI . Rapidly equilibrating carcass tissue and plasma 
C2 Slowly equilibrating carcass tissue 
I Gastrointestinal 
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11 Gastrointestinal equilibrium plasma, region 1 
12 Gastrointestinal lumen, region 2 
13 Gastrointestinal lumen, region 3 
14 Gastrointestinal lumen, region 4 
15 Gastrointestinal lumen, region 5 
IL Total gastrointestinal lumen 
L Liver 
LI Rapidly equilibrating liver tissue and plasma 
L2 Slowly equilibrating liver tissue 
P Arterial and venous plasma 
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RECOMMENDATIONS 
The physiologically based pharmacokinetic model adequately described 
concentration profiles following oral administration of CTC (+ citrate); 
however, the IV data could not be described by the same model. To 
adequately represent the fowl's natural physiology, the existing model 
may require certain refinements (e.g., additional compartments, nonlinear 
binding, and/or nonlinear transport). In this section, additional 
experiments are suggested that will provide the information necessary to 
ameliorate the present model so that it more closely represents 
physiological reality. 
Tissue sampling: In this study, selected tissues were sampled at 
3 different times after drug administration. Although the tissue groups 
sampled comprise the majority of the bird's total weight, tissues not 
sampled (e.g., bone) could function as reversible sinks. Future 
experiments should include a study of CTC partitioning in all turkey 
tissues. The assumption that compartments are well-mixed could be 
tested with intratissue sampling. The sampling frequency is important 
because nonlinearities cannot be discovered or described without 
sufficient tissue sampling. 
Binding: Although this study assumes linear tissue binding, there 
are circumstances when nonlinear binding may exist. For example, high 
concentrations (e.g., IV dosing) of CTC could cause binding sites to 
become saturated. Since information describing binding of tetracyclines 
in turkey tissues is unavailable, binding experiments are needed. In 
particular, the concentration of CTC at Which saturation occurs should be 
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determined. 
Elimination routes: Model estimates of the fraction of CTC 
eliminated by various routes compare favorably with experimental data 
reported for dogs and rats. However, because birds differ anatomically 
from dogs and rats, similar experiments need to be conducted in turkeys. 
In addition, since CTC chemically decomposes, reaction rates must be 
estimated in tissues and wastes (urine and feces). These experiments 
would provide information on drug elimination and data to test for 
conservation of mass. 
Gastrointestinal processes: In the present model, the 
gastrointestinal lumen was represented by a series of well-mixed tanks. 
Lumen flow between tanks was assumed constant. However, results from 
previous investigations indicate that the flow rate of gut contents 
decreases from the proximal to distal portions of the gastrointestinal 
tract. Such studies need to be carried out in the fowl; they require 
data on tracer (nonabsorbable) distribution as a function of time and 
position. Another parameter that varies with position along the 
gastrointestinal tract is the permeability. Experiments should be 
conducted to determine gut permeabilities in different segments of the 
turkey's gastrointestinal tract. 
Diseased state: Although the effects fowl cholera has on 
pharmacokinetics can be hypothesized, the theories cannot be verified 
without further experimentation on infected birds. Tissue concentrations 
in diseased birds need to be determined so that permeabilities can be 
estimated. Whenever possible, other model parameters should be 
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determined by model independent methods. For example, the fecal flow, 
renal clearance, and fraction bound can be determined by tracer 
experiments, urine collection, and equilibrium dialysis, respectively. 
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CONCLUSIONS 
The principal conclusions were the following: 
1) The plasma response, measured as the area under the 
concentration-time curves, indicated that the amount of CTC absorbed was 
nearly linearly related to the dose (10, 15, 20 mg CTC/kg orally). 
2) The concentration of CTC was considerably higher in the liver 
and kidney than in the muscle and brain at all sample times (2.5, 8.0, 
24.0 hrs). 
3) The time-course of CTC in the plasma and tissues following the 
oral administration of CTC to turkeys was adequately described by a 
physiologically based pharmacokinetic model. 
4) The low values of permeabilities (k_), relative to the regional 
plasma flows (Q^ ), indicate that tissue permeability limits CTC 
distribution. 
5) Based on model simulations, the fractions of dose eliminated 
by renal excretion, biliary secretion, and chemical decomposition are 
50%, 46%, and 4%, respectively. 
6) The addition of citric acid to an oral dosage mixture (7 g/I 
CTC, 70 g/1 citrate, 0.3 g/1 Ca^ "*", 0-1 g/1 Mg^ )^ produces significantly 
higher plasma levels than when citrate is omitted. The higher plasma 
concentrations were accounted for by a model of competitive binding of 
CTC and citrate to metal cations. Citric acid appears to bind to 
metal cations, thereby preventing their interference with the 
absorption of CTC. 
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7) Based on model simulations, the addition of citric acid to a 
CTC (7 g/1) mixture containing Ca^  ^(0.3 g/1) and Mg^ "*" (0,1 g/1) increases 
the unbound fraction of CTC in the lumen from 0.34 to 0.98, and the 
fraction of dose absorbed from 0.06 to 0.16. 
8) Following oral administration of CTC, birds infected with 
2" multocida had significantly higher plasma levels than healthy birds. 
9) Although the effects that fowl cholera has on the 
pharmacokinetics were not fully characterized, the model indicates that 
intestinal permeability is higher in infected birds and, in addition, 
renal and/or hepatic clearances are reduced. 
10) Concentration profiles in the plasma following intravenous 
administration of CTC declined more rapidly than those predicted by 
the model. 
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APPENDIX; COMPUTER PROGRAMS 
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C PROGRAM #1 -
C 
C 
C ORAL MODEL: G.I. TRACT MODELED BY 4 TANKS IN SERIES 
C 
C WRITTEN BY: BOB FOLLET 
C 
C PROGRAM IS WRITTEN IN WATFIV 
C 
C REFERENCE: ELEMENTARY DIFFERENTIAL EQUATIONS & BOUNDRY 
C VALUE PROBLEMS, 1977 
C W.E. BOYCE R.C. DIPRIMA PP304-321 
C 
C 
C 
C EXPLICIT DECLARATION OF ALL VARIABLES 
INTEGER FLAG(12),I,IA,IDGT,IER,IJ0B,IZ,J 
INTEGER LUNFLO,M,N,NUM,P 
DOUBLE PRECISION A(ll,ll),B(11,1),BR,CL,CLT(10) 
DOUBLE PRECISION CMT(IO),C0SI(11),CP(10),DM,E(11),EE(11) 
DOUBLE PRECISION F,F2,F3,F4,F5,F6,FB,FI,FL,FM,IW(11) ,K(11) 
DOUBLE PRECISION KI,KI2,KI3,KI4,KI5,KI6,KL,KM,KR,ML2,MM2 
DOUBLE PRECISION PAR(ll),P0WER(11),PR(11),QB,QF,QI,QL,QM,QP 
DOUBLE PRECISION RW(22),RZ(242),SINE(11),SSQ,SSQL,SSQM,SSQP,T 
DOUBLE PRECISION TEST(ll),VI1,VI2,VI3,VI4,VI5,VI6 
DOUBLE PRECISION V(ll,11),VL1,VM1,VP 
DOUBLE PRECISION WK(143),WKAREA(154),WT(11),X(11) 
REAL*8 DREAL,DIMAG 
C0MPLEX*16 W(11),Z(11,11),ZN 
EQUIVALENCE (W(l),RW(1)),(Z(l,1),RZ(1)) 
NUM=11 
C PREVENTS EXPONENTIAL UNDERFLOW 
LUNFLO=100 
CALL TRAPS(0,0,LUNFLO,0,0) 
C 
C VALUES OF PARAMETERS 
C 
C DENSITY OF CARCASS COMPARTMENT 
DM=1.05DO 
C FRACTION OF CTC UNBOUND IN PLASMA 
F=.59D0 
C UNBOUND FRACTION IN BILE 
FB=.59D0 
C UNBOUND FRACTION IN LIVER TISSUE 
FL=.59D0 
C UNBOUND FRACTION IN CARCASS TISSUE 
FM=.59D0 
C UNBOUND FRACTION IN INTESTINAL LUMEN 
FI=.75D0 
C COEFFICIENT DESCRIBING TRANSPORT INTO LIVER TISSUE,ML/MIN 
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KL=4.7D0 
BILIARY FLOW RATE, ML/MIN 
QB=.05D0 
RATIO OF BILE CONG. TO LIVER CONC., CB/CL2 
BR=20.DO 
RENAL CLEARANCE, ML/MIN 
CL=5.IDO 
FECAL FLOW RATE, ML/MIN 
QF=.133D0 
DECOMPOSITION RATE CONSTANT, 1/MIN 
KR=.00015DO 
INTESTINAL PERMEABILITY IN MIDDLE PORTION OF SMALL INTESTINE 
ML/MIN 
KI=.00587D0 
RATIO OF INTES. PERMEABILITY IN LUMEN 1 TO LUMENS 
KI2/KI4 
F2=.8D0 
KI3/KI4 
F3=l.8D0 
KI4/KI4 
F4=1.D0 
KI5/KI4 
F5=.77D0 
PROGRAM SET UP WITH AN EXTRA LUMEN TANK; SINCE ONLY 4 TANKS 
REQUIRED TO DESCRIBE EXIT AGE DISTRIBUTION IN FECES, LAST 
TANK NOT USED THEREFORE F6=KI6-0 
F6=0.D0 
DETERMINE PERMEABILITIES IN EACH LUMEN REGION (RATIOS OF EACH 
OTHER) , ML/MIN 
KI2=F2"KI 
KI3=F3"KI 
KI4=F4*KI 
KI5=F5"KI 
KI6=0.D0 
CARCASS PERMEABILITY, ML/MIN 
KM=5.5D0 
MASS OF SLOW EQUIL. LIVER TISSUE, G 
ML2=22.8D0 
MASS OF SLOW EQUIL. CARCASS TISSUE, G 
MM2=2358.D0 
INTESTINAL PLASMA FLOW RATE, ML/MIN 
QI=36.2D0 
LIVER PLASMA FLOW RATE, ML/MIN 
QL=60.7D0 
CARCASS PLASMA FLOW RATE, ML/MIN 
QM=258.8D0 
TOTAL PLASMA FLOW RATE,ML/MIN 
QP=319.5D0 
VOLUME OF PLASMA IN INTESTINE, ML 
VI1=7.3D0 
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C VOLUME OF LUMEN REGIONS 
VI2=7.DO 
VI3=15.67D0 
VI4=15.67D0 
VI5=15.67D0 
VI6=15.67D0 
C VOLUME OF RAPIDLY EQUIL. LIVER TISSUE+PLASMA, ML 
VL1=24.D0 
C VOLUME OF RAPIDLY EQUIL. CARCASS TISSUE+PLASMA, ML 
VM1=482.6D0 
C VOLUME OF PLASMA IN ARTERIES AND VEINS 
VP=115.6DO 
C 
C 
C THE SYSTEM, C'=AC CO=B , IS TO BE SOLVED 
C 
C SINCE MANY OF THE CHARACTORS IN MATRIX A EQUAL ZERO, 
C INITIALLY SET A=0 
DO 20 1=1,11 
DO 10 J=l,ll 
A(I,J)=O.DO 
10 CONTINUE 
20 CONTINUE 
C 
C MASS BALANCES WERE PERFORMED ON FREE COMPONENT OF 
C CP,CI1-CI6,CL1,CM1; TOTAL COMPONENT OF CL2,CM2 
C 
C 
C VALUES IN MATRIX A DESCRIBING: 
C 
C TRANSPORT OF CTC IN PLASMA FLOW FROM LIVER TO PLASMA COMP. 
A(1,4)=QL/VP 
C XPORT TO PLASMA FROM CARCASS 
A(1,6)=QM/VP 
C XPORT OUT OF PLASMA COMP. 
A(1,1)=-(QP+(CL*F)+(VP*KR*F))/VP 
C XPORT TO INTESTINAL PLASMA FROM ARTERIES 
A(2,1)=QI/VI1 
C XPORT INTO INTES. PLASMA FROM LUMEN SEGMENT 1 
A(2,3)=KI2*F/VI1 
C XPORT & ELIM. FROM INTESTINAL PLASMA 
A(2,2)=-((F*(KI2+KI3+KI4+KI5+KI6))+QI+(F*VI1*KR))/VI1 
C XPORT INTO INTES. PLASMA FROM LUMEN SEGMENTS 2-4 
A(2,8)=KI3*F/VI1 
A(2,9)=KI4*F/VI1 
A(2,10)=KI5*F/VI1 
A(2,11)=KI6*F/VI1 
C XPORT INTO UPPER SEGMENT OF G.I. LUMEN FROM INTES. PLASMA 
A(3,2)=KI2*FI/VI2 
C XPORT & ELIM. FROM UPPER INTES. LUMEN 
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A(3,3)=-(((QF+(VI2*KR*FI))/VI2)+(KI2*FI/VI2)) 
C XPORT BY PLASMA FLOW INTO RAPIDLY EQUIL. (RE) LIVER TISSUE 
A(4,2)=QI/VL1 
A(4,1)=(QL-QI)/VL1 
C XPORT & ELIM. FROM RE LIVER TISSUE 
A(4,4)=-( (F-"-KL)+QL+(VLl*KR*F) )/VLl 
C XPORT TO SLOWLY EQUIL. (SE) LIVER TISSUE FROM RE LIVER TISSUE 
A(5,4)=KL/ML2 
C XPORT & ELIM. FROM SE LI\'ER TISSUE 
A(5,5)=-((KR*FL)+((QB*BR)/ML2)) 
C XPORT INTO RE CARCASS TISSUE BY PLASMA FLOW 
A(6,1)=QM/VM1 
C XPORT INTO RE CARCASS TISSUE FROM SE CARCASS TISSUE 
A(6,7)=(KM*F*FM*DM)/VMl 
C XPORT & ELIM. FROM RE CARCASS TISSUE 
A(6,6)=-(QM+(F*KM)+(F*VM1*KR))/VM1 
C XPORT INTO SE CARCASS FROM RE CARCASS 
A(7,6)=KM/MM2 
C XPORT & ELIM. FROM SE CARCASS TISSUE 
A(7,7)=-(((FM*KM*DM)/(MM2))+((MM2*KR*FM)/MM2)) 
C XPORT INTO INTES. LUMEN SEGMENT 2 FROM LUMEN PLASMA 
A(8,2)=KI3*FI/VI3 
C XPORT INTO LUMEN SEGMENT 2 FROM SEGMENT 1 BY FECAL FLOW 
A(8,3)=QF/VI3 
C BILIARY XPORT (FLOW) INTO LUMEN 2 
A(8,5)=(QB*BR*FI)/VI3 
C XPORT & ELIM. FROM INTES. LUMEN SEG. 2 
A(8,8)=-((QF/VI3)+(KR*FI)+(KI3*FI/VI3)) 
C XPORT INTO LUMEN 3 FROM PLASMA 
A(9,2)=KI4*FI/VI4 
C XPORT INTO LUMEN 3 BY FECAL FLOW 
A(9,8)=QF/VI4 
C XPORT & ELIM. FROM INTES. LUMEN 3 
A(9,9)=-((QF/VI4)+(KR*FI)+(KI4*FI/VI4)) 
C XPORT & ELIM. INTO LUMEN 4 FROM PLASMA 
A(10,2)=KI5*FI/VI5 
C XPORT INTO LUMEN 4 BY FECAL FLOW 
A(10,9)=QF/VI5 
C XPORT. & ELIM. FROM INTES. LUMEN SEGMENT 4 
A(10,10)=-((QF/VI5)+(KR*FI)+(KI5*FI/VI5)) 
C THE LAST 3 TERMS OF MATRIX 'A' DESCRIBE A 5TH INTES. 
C LUMEN SEGMENT; SINCE ONLY 4 LUMEN SEGMENTS ARE USED TO 
C DESCRIBE FECAL XPORT IN THE TURKEY GUT THESE TERMS ARE NOT 
C IMPORTANT IN THE MODEL (I.E. KI6=0) 
A(11,2)=KI6*FI/VI6 
A(11,10)=QF/VI6 
A(11,11)=-((QF/VI6)+(KR-^ FI)+(KI6-^ FI/VI6)) 
C 
C 
C THE FIRST STEP IN SOLVING THE SYSTEM OF LINEAR FIRST 
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C ORDER HOMOGENEOUS ORDINARY DIFF. EQUATIONS WITH 
C CONSTANT COEFFICIENTS IS TO SOLVE MATRIX 'A' FOR IT'S 
C EIGENVALUES & EIGENVECTORS, (A-RI)V=0 R=EIGENVALUES 
C V=EIGENVECTORS. WITH NO REPEATED OR COMPLEX ROOTS THE SOLN. 
C IS OF THE FORM; X=SUM K*V*EXP(R*T), K=CONSTANT 
C 
C IMSL ROUTINE EIGRF IS USED TO DETERMINE THE EIGENVALUES OF 
C MATRIX 'A' 
C 
C 
C ORDER OF MATRIX 'A' 
N=NUM 
C ROW DIMENSION OF MATRIX 'A' 
IA=NUM 
C INPUT OPTION PARAMETER: CALC. EIGENVALUES,EIGENVECTORS 
IJ0B=2 
C ROW DIMENSION OF OUTPUT MATRIX 
IZ=NUM 
CALL EIGRF(A,N,IA,IJOB,RW,RZ,IZ,WK,IER) 
C THE EIGENVECTORS ARE STORED IN MATRIX 'V' 
DO 40 J=1,NUM 
DO 30 1=1,NUM 
V(I,J)=Z(I,J) 
30 CONTINUE 
40 CONTINUE 
C 
C 
C WARNING: THIS PROGRAM IS NOT DESIGNED TO HANDLE REPEATED ROOTS 
C UNLESS ALL THE EIGENVECTORS ARE LINEARLY (SUM CV=0) INDEPENDENT 
C 
C 
C IF MATRIX 'A' (OF C'=AC) IS REAL, ANY COMPLEX EIGENVALUES 
C MUST OCCUR IN CONJUGATE PAIRS, R1=F+GI R2=F-GI 
C IN ADDITION, THE CORRESPONDING EIGENVECTORS ARE COMPLEX 
C CONJUGATES, V1=L+MI V2=L-MI 
C THEREFORE, THE SOLUTIONS ARE COMPLEX CONJUGATES OF EACH OTHER. 
C THE FORM OF THE PORTION OF A SOLUTION CORRESPONDING TO A PAIR 
C OF COMPLEX CONJUGATES IS=K1*(EXP(F*T))*(L*C0S(G*T)-M*SIN(G*T)) 
C +K2* (EXP (F^ -T)  * ( L*S IN ( G*T) +M*COS (G-^ ) ) 
C SINCE COPLEX EIGENVALUES LEAD TO A SOLUTION CONTAINING SINE 
C AND COSINE TERMS, FLAGS ARE USED TO CHECK FOR COMPLEX ROOTS 
C FLAG=0 :REAL ROOT; FLAG=1 : COMPLEX ROOT; 
C FLAG=2 : COMPLEX CONJUGATE ROOT 
C 
FLAG(1)=0 
DO 60 1=1,NUM 
P=I+1 
IF(FLAG(I).NE.2)THEN 
C EXTRACT IMAGINARY PORTION OF EIGENVALUE USING LIBRARY 
C FUNCTION 'DIMAG' 
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IW(I)=DIMAG(W(I)) 
TEST(I)=DABS(IW(I)) 
IF(TEST(I).GT.0.0000001DO)THEN 
FLAG(I)=1 
DO 50 J=1,NUM 
V(J,I)=DREAL(Z(J,I)) 
V(J,P)=DIMAG(Z(J,I)) 
FLAG(P)=2 
50 CONTINUE 
ELSE 
FLAG(P)=0 
END IF 
ELSE 
FLAG(P)=0 
END IF 
60 CONTINUE 
C 
C 
C AT TIME=0 THE EXPONENTIAL TERMS IN THE SOLUTION ARE ZERO; 
C THEREFORE THE SOLUTION AT T=0 IS OF THE FORM: VK=B 
C V=MATRIX OF EIGENVECTORS, B=VECTOR OF INITIAL CONDITIONS 
C THE CONSTANTS(K) MUST BE SOLVED FOR BY SOLVING THE LINEAR 
C SYSTEM VK=B IMSL ROUTINE LEQT2F WAS EMPLOYED 
C 
C M=# OF RIGHT HAND SIDES OF VK=B 
M=1 
C INPUT OPTION: PERFORMS ACCURACY TEST 
IDGT=3 
C SET BOUNDRY CONDITIONS: CONCENTRATIONS AT TIME = 0 IN ALL 
C REGIONS EXCEPT INTES. LUMEN 1 EQUAL 0 
DO 70 1=1,NUM 
70 BCI,1)=0.D0 
BC3,1)=(49500.D0"FI)/VI2 
CALL LEQT2F(V,M,N,IA,B,IDGT,WKAREA,IER) 
C 
C 
C 
C ON OUTPUT B=CONSTANTS 
C REDEFINE CONSTANTS (DESCRIBED ABOVE AS K) 
C 
DO 75 1=1,NUM 
KCI)=B(I,1) 
75 CONTINUE 
C 
C 
C 
C CALCULATE CONCENTRATIONS AT VARIOUS TIMES 
C 
C DEFINE TIMES (T) AT WHICH SOLUTIONS ARE DESIRED 
C STEPPING OFF TIME 
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DO 95 M=l,10 
IF(M.EQ.1)THEN 
T=O.DO 
ELSE 
IF(M.EQ.2)THEN 
T=15.D0 
ELSE 
IF(M.EQ.3)THEN 
T=30.D0 
ELSE 
IF(M.EQ.4)THEN 
T=60.D0 
ELSE 
IF(M.EQ.5)THEN 
T=2.5D0*60.D0 
ELSE 
IF(M.EQ.6)THEN 
T=3.D0*60.D0 
ELSE 
IF(M.EQ.7)THEN 
T=4.5D0*60.D0 
ELSE 
IF(M.EQ.8)THEN 
T=8.D0*60.D0 
ELSE 
IF(M.EQ.9)THEN 
T=12.D0*60.D0 
ELSE 
T=24.D0*60.D0 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
C 
C 
C 
DO 80 1=1,NUM 
C FOR IMAGINARY ROOTS, SEPARATE ROOTS INTO REAL AND IMAGINARY 
C PARTS USING LIBRARY FUNCTIONS 'DIMAG'(PERFORMED EARLIER=IW(I)) 
C AND 'DREAL' RESPECTIVELY. BOTH REAL & IMAG. PORTIONS ARE THEN 
C MULTIPLIED BY TIME (T). SINE, COSINE, & EXPONENTIAL FUNCTIONS 
C OF TIME ARE ALSO SOLVED SINCE NEEDED IN TOTAL SOLUTION 
C DESCRIBED EARLIER. 
C 
IF (FLAG(I).EQ.1)THEN 
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PR(I)=DREAL(W(I)) 
POWER(I)=PR(I)*T 
PAR(I)=IW(I)*T 
C PREVENT EXPONENTIAL UNDERFLOW 
IF(POWER(I).LT.-150.DO)THEN 
POWER(I)=-150.D0 
ELSE 
CONTINUE 
END IF 
EE(I)=DEXP(POWER(I)) 
SINE(I)=DSIN(PAR(I)) 
COSI(I)=DCOS(PAR(I)) 
ELSE 
IF(FLAG(I).EQ.O)THEN 
WT(I)=W(I)*T 
C PREVENT EXPONENTIAL UNDERFLOW 
IF(WT(I).LT.-150.DO)THEN 
WT(I)=-150.D0 
ELSE 
CONTINUE 
END IF 
E(I)=DEXP(WT(I)) 
ELSE 
CONTINUE 
END IF 
END IF 
80 CONTINUE 
C 
C 
C EXPRESSIONS TO CALCULATE CONCENTRATIONS (X(I)) AT VARIOUS TIMES; 
C PARTIAL SOLUTIONS ARE SUMMED UP TO GET SOLUTION(CONCENTRATIONS) 
C AS A FUNCTION OF TIME (AT TIMES REQUESTED). 
C 
DO 90 1=1,NUM 
X(I)=0.D0 
DO 85 J=1,NUM 
P=J+1 
IF (FLAG(J).EQ.0)THEN 
X(I)=K(J)*Z(I,J)*E(J)+X(I) 
ELSE 
IF(FLAG(J).EQ.1)THEN 
X(I)=X(I)+(K(J)*EE(J)*(V(I,J)*COSI(J)-V(I,P)*SINE(J)))+ 
* (K(P)*EE(J)*(V(I,J)*SINE(J)+V(I,P)*COSI(J))) 
ELSE 
CONTINUE 
END IF 
END IF 
85 CONTINUE 
90 CONTINUE 
C 
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C COMPARTMENTS: CONC PLASMA=X(1), CONC INTESTINAL PLASMA=X(2), 
C CONC. INTES. LUMEN1=X(3), CONC. RAPID EQUIL. LIVER=X(4), 
C CONC. SLOW EQUIL. LIVER=X(5), CONC. RAPID EQUIL. CARCASS= 
C X(6), CONC. SLOW EQUIL. CARCASS=X(7), CONC. INTES. LUMEN 
C SEGMENT 2=X(8), CONC. INTES. LUMEN SEG.3=X(9) 
C CONC. INTES. LUMEN SEG. 4=X(10) 
C 
C SINCE EXPERIMENTAL TISSUE DATA CONTAINS PLASMA, MODEL TISSUES 
C (LIVER, CARCASS) MUST BE THE VOLUME AVERAGE OF PLASMA & TISSUE. 
C 
CP(M)=X(1) 
CLT(M)=((ML2*X(5))+(28.8D0*X(4)/F))/53.DO 
CMT(M)=((MM2*X(7))+(VMl*X(6)/F))/(MM2+(VM1*DM)) 
C 
C 
PRINT, 'AT TIME=',T 
PRINT,'CP=',X(1),'CIP=',X(2),'CIC=',X(3),'CLP=',X(4) 
* ,'CLT=',CLT(M),X(5),'CMP=',X(6),'CMT=',CMT(M),X(7) 
PRINT,'CI3=',X(8),'CI4=',X(9),'CI5=',X(10),'CI6=',X(11) 
95 CONTINUE 
C 
C 
C CALCULATE SUM OF SQUARES 
C 
C PLASMA SSQ=SSQP; LIVER SSQ=SSQL; CARCASS SSQ=SSQM 
C 
SSQP=(.35D0-CP(2))'^ 2^+(.58D0-CP(3))*^ '-2+(.8D0-CP(4))^ '-'-2 
* +(1.IDO-CP(5))**2+(1.16D0-CP(6))**2+(.74D0-CP(7))**2+ 
* (.44D0-CP(8))**2+(.23D0-CP(9))**2+(.11D0-CP(10))**2 
SSQL=(3.05D0-CLT(5))**2+(2.32D0-CLT(8))**2+(.6IDO-CLT(10))**2 
SSQM=(.23D0-CMT(5))**2+(.28D0-CMT(8))**2+(.05D0-CMT(10))**2 
SSQ=SSQP+SSQL+SSQM 
PRINT,'SSQP=',SSQP,'SSQL=',SSQL,'SSQM=',SSQM,'SSQ=',SSQ 
STOP 
END 
$ENTRY 
90 
C - PROGRAM #2 -
C 
C 
C NUMERICAL SOLUTION TO THE ORAL MODEL: G.I. TRACT MODEL AS ONE 
C VARIABLE VOLUME STIRRED TANK 
C 
C WRITTEN BY: BOB FOLLET 
C PROGRAM IS WRITTEN IN WATFIV 
C 
C 
c 
C EXPLICIT DECLARATION OF ALL VARIABLES 
INTEGER I,IER,INDEX,IWK(7),M,METH,MITER,N 
DOUBLE PRECISION A(7,7),BR,C(7),CL,CL2,CM2,DM 
DOUBLE PRECISION F,FB,FI,FL,FM,H,KI,KL,KM,KR 
DOUBLE PRECISION ML2,MM2,QB,QF,QI,QL,QM,QP,T,TAU,T0L 
DOUBLE PRECISION VI1,VI2,VL1,VM1,VP,WK(126),X,XEND,Y(7) 
EXTERNAL FCN.FCNJ 
C0MM0N/VAR/A,F,FI,KI,KR,ML2,MM2,QF,QI,VI1,VI2,VL1,VM1,VP 
C 
C 
C VALUES OF PARAMETERS 
C 
C DENSITY OF CARCASS COMPARTMENT 
DM=1.05D0 
C FRACTION OF CTC UNBOUND IN PLASMA 
F=.59D0 
C UNBOUND FRACTION IN BILE 
FB=.59D0 
C UNBOUND FRACTION IN LIVER TISSUE 
FL=.59D0 
C UNBOUND FRACTION IN CARCASS TISSUE 
FM=.59D0 
C UNBOUND FRACTION IN INTESTINAL LUMEN 
FI=.75D0 
C COEFFICIENT DESCRIBING TRANSPORT INTO LIVER TISSUE,ML/MIN 
KL=4.7D0 
C BILIARY FLOW RATE, ML/MIN 
QB=.05D0 
C RATIO OF BILE CONC. TO LIVER CONC., CB/CL2 
BR=20.D0 
C RENAL CLEARANCE, ML/MIN 
CL=5.IDG 
C FECAL FLOW RATE, ML/MIN 
C MATERIAL IS NOT ELIMINATED IN FECES UNTIL LEAVING LARGE INTEST. 
C (T.GT.TAU);CONSEQUENTLY, AT T=0 QF=0 
QF=O.DO 
C DECOMPOSITION RATE CONSTANT, 1/MIN 
KR=.00015D0 
C INTESTINAL PERMEABILITY IN GASTROINTESTINAL TRACT AT T=0 
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C INITALLY DRUG COVERS ONLY A PORTION OF G.I. TRACT SURFACE AREA 
c ML/MIN 
KI=.034DO"7.DO/54.DO 
c CARCASS PERMEABILITY, ML/MIN 
KM=5.5D0 
c MASS OF SLOW EQUIL. LIVER TISSUE 
ML2=22.8D0 
c MASS OF SLOW EQUIL. CARCASS TISSUE, G 
MM2=2358.D0 
c INTESTINAL PLASMA FLOW RATE, ML/MIN 
QI=36.2D0 
c LIVER PLASMA FLOW RATE, ML/MIN 
QL=60.7D0 
c CARCASS PLASMA FLOW RATE, ML/MIN 
QM=258.8D0 
c TOTAL PLASMA FLOW RATE,ML/MIN 
QP=319.5D0 
c VOLUME OF PLASMA IN INTESTINE, ML 
VI1=7.3D0 
c INITIAL VOLUME OF LUMEN REGION 
VI2=7.DO 
c VOLUME OF RAPIDLY EQUIL. LIVER TISSUE+PLASMA, ML 
VL1=24.D0 
c VOLUME OF RAPIDLY EQUIL. CARCASS TISSUE+PLASMA, ML 
VM1=482.6D0 
c VOLUME OF PLASMA IN ARTERIES AND VEINS 
c 
VP=115.6D0 
c 
c 
p 
THE SYSTEM, M'=AM MO=B , IS TO BE SOLVED 
c SINCE MANY OF THE CHARACTORS IN MATRIX A EQUAL ZERO, 
c INITIALLY SET A=0 
DO 20 1=1,7 
DO 10 J=l,7 
A(I,J)=O.DO 
10 CONTINUE 
20 CONTINUE 
C 
C MASS BALANCES WERE PERFORMED ON TOTAL CTC (M) IN EACH 
C COMPARTMENT 
C 
C SYSTEM: M'=AM M=VECTOR DESCRIBING MASS OF DRUG IN EACH COMP. 
C 
C 
C VALUES IN MATRIX A DESCRIBING: 
C 
C TRANSPORT OF CTC IN PLASMA FLOW FROM LIVER TO PLASMA COMP. 
A(1,4)=QL/VL1 
C XPORT TO PLASMA FROM CARCASS 
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A(1,6)=QM/VM1 
C XPORT & ELIM. FROM PLASMA COMPART. 
A ( 1,1 )=(QP+ (CL*F)+(VP'"^KR*F) ) /VP 
C XPORT TO INTESTIAL PLASMA FROM PLASMA COMPARTMENT 
A(2,1)=QI/VP 
C XPORT INTO INTES. PLASMA FROM LUMEN 
A(2,3)=(KI*FI)/VI2 
C XPORT & ELIM. FROM INTESTINAL PLASMA 
A(2,2)=((F*KI)+QI+(F*VI1*KR))/VI1 
C XPORT BY BILIARY FLOW FROM LIVER TO INTES. LUMEN 
A(3,5)=(QB*BR)/ML2 
C XPORT INTO G.I. LUMEN FROM INTES. PLASMA 
A(3,2)=(KI*F)/VI1 
C XPORT & ELIM. FROM G.I. LUMEN 
A(3,3)=((KI*FI)+QF+(VI2*KR*FI))/VI2 
C XPORT BY PLASMA FLOW INTO RAPIDLY EQUIL.(RE) LIVER TISSUE 
A(4,2)=QI/VI1 
A(4,1)=(QL-QI)/VP 
C XPORT & ELIM. FROM RE LIVER TISSUE 
A(4,4)=((F*KL)+QL+(VL1*KR*F))/VL1 
C XPORT TO SLOWLY EQUIL. (SE) LIVER TISSUE FROM RE LIVER TISSUE 
A(5,4)=KL*F/VL1 
C XPORT & ELIM. FROM SE LIVER TISSUE 
A(5,5)=((KR*FL*ML2)+(QB*BR))/ML2 
C XPORT INTO RE CARCASS TISSUE BY PLASMA FLOW 
A(6,1)=QM/VP 
C XPORT INTO RE CARCASS TISSUE FROM SE CARCASS TISSUE 
A(6,7)=(KM*FM*DM)/MM2 
C XPORT & ELIM. FROM RE CARCASS TISSUE 
A(6,6)=(QM+(F*KM)+(F*VM1*KR))/VM1 
C XPORT INTO SE CARCASS FROM RE CARCASS 
A(7,6)=(KM*F)/VM1 
C XPORT & ELIM FROM SE CARCASS TISSUE 
A(7,7)=((FM*KM*DM)+(MM2*KR*FM))/MM2 
C 
C 
C IMSL ROUTINE 'DGEAR' USED FOR NUMERICAL INTEGRATION 
C 
C 
C SPECIFICATION PARAMETERS FOR IMSL ROUTINE 'DGEAR' 
C 
C INPUT ITERATION INDICATOR ( MITER=2, CHORD METHOD USED WITH 
C THE JACOBIAN CALCULATED INTERNALLY BY FINITE DIFFERENCES) 
MITER=2 
C INPUT AND OUTPUT PARAMETER INDICATING THE TYPE OF CALL TO 
C SUBROUTINE (INDEX=1, IMPLIES FIRST CALL FOR THIS PROBLEM) 
INDEX=1 
C INPUT BASIC METHOD INDICATOR (METH0D=2, IMPLIES THE STIFF 
C METHODS OF GEAR, OR THE BACKWARD DIFFERENTIATION FORMULAE 
C ARE TO BE USED) 
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METH=2 
C NUMBER OF FIRST ORDER DIFFERENTIAL EQUATIONS 
N=7 
C INDEPENDENT VARIABLE (TIME) 
C ON INPUT, X SUPPLIES THE INITIAL VALUE OF TIME 
C ON OUTPUT, X REPLACED WITH CURRENT VALUE OF OF INDEP. 
C VARIABLE AT WHICH INTEGRATION HAS BEEN COMPLETED. 
X=0.DO 
C INPUT RELATIVE ERROR BOUND 
TOL=.O001D0 
C STEP SIZE: ON INPUT, INITIAL STEP SIZE IN X 
C ON OUTPUT, STEP SIZE USED LAST 
H=.00001DO 
C 
C 
C DEPENDENT VARIABLES (MASS OF DRUG IN EACH COMPARTMENT) 
C ON INPUT Y(I) SUPPLIES INITIAL VALUES 
C ON OUTPUT Y(I) REPLACED WITH COMPUTED VALUE AT XEND 
C 
C INITIALLY (T=0) MASS OF CTC IN ALL COMPARTMENTS EXCEPT 
C GUT LUMEN (Y(3)) EQUALS ZERO. 
C 
Y(1)=0.D0 
Y(2)=0.D0 
Y(3)=49500.D0 
Y(4)=0.D0 
Y(5)=0.D0 
Y(6)=O.DO 
Y(7)=0.D0 
C 
C 
C TIMES (T) AT WHICH SOLUTIONS ARE DESIRED 
C STEPPING OFF TIME 
C 
DO 30 M=l,ll 
IF(M.EQ.1)THEN 
T=15.D0 
ELSE 
IF(M.EQ.2)THEN 
T=30.D0 
ELSE 
IF(M.EQ.3)THEN 
T=60.D0 
ELSE 
IF(M.EQ.4)THEN 
T=90.DO 
ELSE 
IF(M.EQ.5)THEN 
T=120.D0 
ELSE 
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IF(M.EQ.6)THEN 
T=2.5D0*60.D0 
ELSE 
IF(M.EQ.7)THEN 
T=3.D0*60.D0 
ELSE 
IF(M.EQ.8)THEN 
T=4.500*60.DO 
ELSE 
IF(M.EQ.9)THEN 
T=8.DO"6O.D0 
ELSE 
IF(M.EQ.10)THEN 
T=12.D0*60.D0 
ELSE 
T=24.D0*60.D0 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
END IF 
C 
C XEND=VALUE OF X (TIME) AT WHICH SOLUTION IS DESIRED 
XEND=T 
C 
C IMSL NUMERICAL DIFFERENTIAL EQUATION SOLVER 'DGEAR' EMPLOYED 
C 
CALL DGEAR(N,FCN,FCNJ,X,H,Y,XEND,TOL,METH,MITER,INDEX,IWK,wK, 
* 1ER) 
C 
C 
C CONCENTRATIONS (MASS/VOLUME) OF UNBOUND OR TOTAL CTC CALCUL. 
C FOR EACH COMPARTMENT 
C 
C(1)=Y(1)*F/VP 
C(2)=Y(2)*F/VI1 
C(3)=Y(3)*FI/VI2 
C(4)=Y(4)*F/VL1 
C(5)=Y(5)/ML2 
C(6)=Y(6)*F/VM1 
C(7)=Y(7)/MM2 
C SINCE EXPERIMENTAL DATA CONTAINS PLASMA, MODEL TISSUES 
C (LIVER,CARCASS) MUST BE THE VOLUME AVERAGE OF PLASMA & TISSUE. 
C 
CL2=((ML2*C(5))+(28.8D0"C(4)/F))/53.D0 
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CM2=((MM2*C(7))+(VMl*C(6)/F))/(MM2+(VMV'n .0200)) 
C 
C 
C PRINT CONCENTRATIONS AS A FUNCTION OF TIME 
PRINT,'AT TIME=',X 
PRINT,'CP=',C(1),'CI1=',C(2),'CI2=',C(3),'CL1=' ,C(4),'CL2=', 
* C(5),'CN1=',C(6),'CM2=',C(7),'MI2=',Y(3) 
PRINT,'IER=',1ER,'CL2 EXPER=',CL2,'CM2 EXPER=',CM2 
30 CONTINUE 
STOP 
END 
C 
c 
C -
c 
c SUBROUTINE FOR EVALUATING FUNCTIONS (Y'(I)=FUNCT(T), 1=1,7) 
C 
C 
SUBROUTINE FCN(N,X,Y,YPRIME) 
INTEGER N 
DOUBLE PRECISION A(7,7),BR,CL,DL2,F,FB,FI,FL,FM 
DOUBLE PRECISION KI,KL,KM,KR,ML2,MM2,QB,QF,QI,QL,QM,QP 
DOUBLE PRECISION TAU,VI1,VI2,VL1,VM1,VP,X,Y(N),YPRIME(N) 
COMMON/VAR/A,F,FI,KI,KR,ML2,MM2,QF,QI,VI1,VI2,VLl,VMl,VP 
C VALUES OF PARAMETERS 
C 
C TIME (MIN) REQUIRED FOR CTC ADMINISTERED IN CROP TO REACH 
C THE END OF THE GASTROINTESTINAL TRACT (LEADING EDGE) 
TAU=60.D0 
C 
C AS CTC DISTRIBUTES THROUGHOUT THE G.I. TRACT LUMEN, DRUG 
C DISTRIBUTES IN TO A LARGER LUMEN VOLUME (VI2), WITH A 
C LARGER SURFACE AREA FOR TRANSFER (SINCE KI IS PROPORTIONAL 
C TO THE SURFACE AREA; INCREASING AREA INCREASES KI) 
C FECAL FLOW BEGINS WHEN MATERIAL REACHES END OF INTES. TRACT. 
C INCREASE IN KI AND VI2 DESCRIBED BY LINEAR FUNCTIONS OF TIME. 
c 
KI=.034D0 
IF(X.LE.TAU)THEN 
VI2=7.D0+((47.DO*X)/TAU) 
KI=(KI*VI2)/54.D0 
•QF=0.D0 
ELSE 
QF=.182D0 
VI2=54.D0 
END IF 
C 
C TRANSPORT OR ELIMINATION PARAMETERS WHICH VARY WITH TIME 
C DESCRIBED EARLIER 
A(2,3)=(KI*FI)/VI2 
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A(2,2)=((F*KI)+QI+(F*VI1*KR))/VI1 
A(3,2)=(KI*F)/VI1 
A(3,3)=((KI*FI)+QF+(VI2*KR*FI))/VI2 
C 
C CHANGE (DERIVATIVE) IN MASS OF CTC IN EACH COMPARTMENT 
G WITH TIME. 
C 
C PLASMA 
YPRIME(1)=A(1,4)*Y(4)+A(1,6)*Y(6)-A(1,1)*Y(1) 
C GASTROINTESTINAL PLASMA 
YPRIME(2)=A(2,1)*Y(1)+A(2,3)*Y(3)-A(2,2)*Y(2) 
G G.I. LUMEN 
YPRIME(3)=A(3,5)*Y(5)+A(3,2)*Y(2)-A(3,3)*Y(3) 
C RAPIDLY EQUILIBRATING LIVER TISSUE 
YPRIME(4)=A(4,2)*Y(2)+A(4,1)*Y(1)-A(4,4)*Y(4) 
C SLOWLY EQUIL. LIVER TISSUE 
YPRIME(5)=A(5,4)*Y(4)-A(5,5)*Y(5) 
G RAPIDLY EQUIL. CARCASS TISSUE 
YPRIME(6)=A(6,1)*Y(1)+A(6,7)*Y(7)-A(6,6)*Y(6) 
C SLOWLY EQUIL. CARCASS TISSUE 
YPRIME(7)=A(7,6)*Y(6)-A(7,7)*Y(7) 
RETURN 
END 
G 
G 
C -
G 
C DUMMY SUBROUTINE TO COMPUTE JACOBIAN MATRIX OF PARTIAL DERIV. 
G 
C 
SUBROUTINE FCNJ(N,X,Y,PD) 
INTEGER N 
DOUBLE PRECISION A(7,7),F,FI,KI,KR,ML2,MM2,PD(N,N),QI,QF 
DOUBLE PRECISION VI1,VI2,VL1,VM1,VP,Y(N),X 
C0MM0N/VAR/A,F,FI,KI,KR,ML2,MM2,QF,QI,VI1,VI2,VL1,VM1,VP 
RETURN 
END 
